Silence Therapeutics plc Deferred Tax Assets, Capital Loss Carryforwards
Silence Therapeutics plc (SLNCF) had Deferred Tax Assets, Capital Loss Carryforwards of $2.65 million as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsCapitalLossCarryforwards · last filed 2026-03-05
- 2025-12-31: Deferred Tax Assets, Capital Loss Carryforwards $2.65M.
- 2024-12-31: Deferred Tax Assets, Capital Loss Carryforwards $2.47M.
- 2023-12-31: Deferred Tax Assets, Capital Loss Carryforwards $2.51M.
| Period end | Deferred Tax Assets, Capital Loss Carryforwards |
|---|---|
| 2025-12-31 | $2.65M 10-K · filed 2026-03-05 |
| 2024-12-31 | $2.47M 10-K · filed 2026-03-05 |
| 2023-12-31 | $2.51M 10-K · filed 2025-02-27 |